Strattera
ADHD
Eli Lilly and CompanyDormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
6 Active assets in the ADHD cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Methylphenidate Hugo W. Moser Research Institute at Kennedy Krieger, Inc. | Phase 4 | BBB |
Olanzapine Washington University School of Medicine | Phase 4 | BB |
Mixed Salts Amphetamine University of Cincinnati | Phase 4 | BB |
Methylphenidate St. Jude Children's Research Hospital | Phase 4 | BB |
Lis-Dexamphetamine Duke University | Phase 4 | B |
View all 11 →
Same molecule, other indications
Strattera is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →